Literature DB >> 22387626

Cerebrospinal fluid Aβ40 and Aβ42: Natural course and clinical usefulness.

M Shoji1, M Kanai.   

Abstract

Amyloid β protein 40 (Aβ40) and 42 (Aβ42), major components of senile plaque amyloids, are physiological peptides present in the brain, cerebrospinal fluid (CSF) and plasma. The levels of CSF Aβ40 and Aβ42(43) show a U-shaped natural course in normal aging. The increase of Aβ42(43) over 60 years of age is inhibited in Alzheimer's disease (AD). This specific alteration of CSF Aβ42(43) correlates with Aβ deposits in the AD brain providing a biological basis for a biomarker of AD. In the GTT2 study, assays of the CSF Aβ ratio [(Aβ40/ Aβ42(43)] showed a diagnostic sensitivity (59%) specificity (88%) The levels of the Aβ ratio increased from early to late stages of AD. Combination assays of CSF tau and Aβ ratio provided further efficient diagnostic sensitivity (81%) reliability of the assay may prompt worldwide usage of these CSF biomarkers for Alzheimer's patients.

Entities:  

Year:  2001        PMID: 22387626

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  6 in total

1.  Soluble amyloid-β levels and late-life depression.

Authors:  Ricardo S Osorio; Tyler Gumb; Nunzio Pomara
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 2.  CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).

Authors:  Craig Ritchie; Nadja Smailagic; Anna H Noel-Storr; Obioha Ukoumunne; Emma C Ladds; Steven Martin
Journal:  Cochrane Database Syst Rev       Date:  2017-03-22

3.  Fibronectin induces the perivascular deposition of cerebrospinal fluid-derived amyloid-β in aging and after stroke.

Authors:  Matthew D Howe; Louise A Atadja; J Weldon Furr; Michael E Maniskas; Liang Zhu; Louise D McCullough; Akihiko Urayama
Journal:  Neurobiol Aging       Date:  2018-08-09       Impact factor: 4.673

4.  Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer's disease.

Authors:  Volker Welge; Oliver Fiege; Piotr Lewczuk; Brit Mollenhauer; Hermann Esselmann; Hans-Wolfgang Klafki; Stefanie Wolf; Claudia Trenkwalder; Markus Otto; Johannes Kornhuber; Jens Wiltfang; Mirko Bibl
Journal:  J Neural Transm (Vienna)       Date:  2009-01-14       Impact factor: 3.575

5.  Neurochemical biomarkers in Alzheimer's disease and related disorders.

Authors:  Mirko Bibl; Hermann Esselmann; Jens Wiltfang
Journal:  Ther Adv Neurol Disord       Date:  2012-11       Impact factor: 6.570

6.  Cerebrospinal fluid soluble TREM2 in aging and Alzheimer's disease.

Authors:  Kristi Henjum; Ina S Almdahl; Vibeke Årskog; Lennart Minthon; Oskar Hansson; Tormod Fladby; Lars N G Nilsson
Journal:  Alzheimers Res Ther       Date:  2016-04-27       Impact factor: 6.982

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.